Regentis Biomaterials

About:

Regentis Biomaterials develops and commercializes proprietary hydrogels for tissue regeneration.

Website: http://www.regentis.co.il

Top Investors: EASME - EU Executive Agency for SMEs, T3, Medica Venture Partners, Generali Investments Europe, SCP Vitalife Partners

Description:

Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials.